RxDoctor Payments Data

Sinead Healey

Acute Care · Cibolo, TXNPI 1568937076

Payments from drug & device makers

$1,804in general payments, 2019–2025

Across 72 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$475
  • Lilly USA, LLC$183
  • Johnson & Johnson$166
  • AstraZeneca$160
  • Pfizer$134
  • Bayer$83
  • plus $603 from 18 others

What the payments were for

  • Food & beverage$1,804100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,804 in reported general payments places this provider in the 80th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$115,642
Medicare patients
346
Services billed
1,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$32,773
OzempicSemaglutide18$18,105
XareltoRivaroxaban21$11,351
MyrbetriqMirabegron15$7,447
Atorvastatin Calcium108$1,266
Donepezil Hcl72$1,172
Memantine Hcl46$1,043
Rosuvastatin Calcium23$904
Levothyroxine Sodium76$828
Gabapentin45$515
Metoprolol Succinate30$509
Omeprazole29$455
Potassium Chloride36$451
Pantoprazole Sodium47$414
Hydralazine Hcl28$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$32,77345 claims
Novo NordiskOzempic$475$18,10518 claims
Johnson & JohnsonXarelto$166$11,35121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,323 acute care providers in Texas.

Other acute care in Cibolo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →